# Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)

> **NCT02955810** · PHASE1 · UNKNOWN · sponsor: **National University of Ireland, Galway, Ireland** · enrollment: 18 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02955810
- **Lead sponsor:** National University of Ireland, Galway, Ireland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2018-09
- **Final completion:** 2020-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955810, "Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02955810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*